Methadone rotation for cancer patients with refractory pain in a palliative care unit: An observational study

Journal of Palliative Medicine

Volumn 16, Issue 11, 2013, Pages 1382-1387

  Rhondali, Wadih ^a,b   Tremellat, Flora ^a,c   Ledoux, Mathilde ^a   Ciais, Jean François ^c   Bruera, Eduardo ^b   Filbet, Marilene ^a  

^a HOSPICES CIVILS DE LYON   (France)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY HOSPITAL OF NICE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FENTANYL; METHADONE; MORPHINE; OXYCODONE;

ADULT; ARTICLE; BRADYPNEA; CANCER PAIN; CANCER PATIENT; CLINICAL ARTICLE; CONTINUOUS INFUSION; DIGESTIVE SYSTEM CANCER; DOULEUR NEUROPATHIQUE 4 SCALE; DROWSINESS; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEAD AND NECK CANCER; HUMAN; LIKERT SCALE; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEUROPATHIC PAIN; NOCICEPTION; PAIN ASSESSMENT; VISUAL ANALOG SCALE;

ADULT; ANALGESICS, OPIOID; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; METHADONE; MIDDLE AGED; NEOPLASMS; PAIN MANAGEMENT; PAIN MEASUREMENT; PAIN, INTRACTABLE; PALLIATIVE CARE; RETROSPECTIVE STUDIES; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME;

EID: 84887924029     PISSN: 10966218     EISSN: 15577740     Source Type: Journal    
DOI: 10.1089/jpm.2013.0222     Document Type: Article

References (41)

1. Portenoy RK: Treatment of cancer pain. Lancet 2011;377: 2236-2247.
2. Elsayem A, Swint K, Fisch MJ, et al: Palliative care inpatient service in a comprehensive cancer center: Clinical and financial outcomes. J Clin Oncol 2004;22:2008-2014.
3. Delgado-Guay M, Yennurajalingam S, Parsons H, et al: Association between self-reported sleep disturbance and other symptoms in patients with advanced cancer. J Pain Symptom Manage 2011;41:819-827.
4. Cleeland CS: Symptom burden: Multiple symptoms and their impact as patient-reported outcomes. J Natl Cancer Inst Monogr 2007:16-21.
5. Bruera E, Hui D: Integrating supportive and palliative care in the trajectory of cancer: Establishing goals and models of care. J Clin Oncol 2010;28:4013-4017.
6. Deandrea S, Montanari M, Moja L, et al: Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol 2008;19:1985-1991.
7. Breivik H, et al.: Cancer related pain: A pan European survey of prevalence, treatment, and patients attitudes. Annals of Oncology 2009;20:1420-1433.
8. World Health Organization. Cancer pain relief: with a guide to opiod availability. 1996 Geneva. http://whqlibdoc.who .int/publications/9241544821.pdf
9. Caraceni A, Hanks G, Kaasa S, et al: Use of opioid analgesics in the treatment of cancer pain: Evidence-based recommendations from the EAPC. Lancet Oncol 2012;13:e58-e68.
10. Riley J, Branford R, Droney J, et al: A randomised controlled trial of oral morphine versus oral oxycodone for the treatment of pain in cancer patients. Palliat Med 2012;26:386 (abstr # PL3).
11. Fine P, Portenoy R: Etablishing "best practices" for opioid rotation: Conclusions of an expert panel. J Pain Symptom Manage 2009;38:418-425.
12. Vadalouca A, Moka E, Argyra E, et al: Opioid rotation in patients with cancer: A review of the current literature. J Opioid Manage 2008;4:213-250.
13. Indelicato R, Portenoy R: Opioid rotation in the management of refractory cancer pain. J Clin Oncol 2002;1: 348-352.
14. Hewitt D: The use of NMDA-receptor antagonists in the treatment of chronic pain. Clin J Pain 2000;16:73-79.
15. Gagnon B, Almahrezi A, Schreier G: Methadone in the treatment of neuropathic pain. Pain Res Manage 2003;8: 149-154.
16. Prommer E: Review: Methadone for cancer pain. Palliat Care Res Treatment 2010;4:1-10.
17. Bruera E, Pereira J, Watanabe S, et al: Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer 1996;78:852-857.
18. Davis M, Walsh D: Methadone for relief of cancer pain: A review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration. Support Care Cancer 2001;9:73-983.
19. Currow DC, Spruyt O, Hardy J: Defining refractory pain in cancer for clinicians and researchers. J PalliatMed 2012;15:5-6.
20. Bruera E, Sweeney C: Methadone use in cancer patients with pain: A review. J Palliat Med 2002;5:127-138.
21. Mercadante S: Stop and go strategy for opioid switching requires flexibility. Eur J Cancer 2012;48:944-945; author reply 946-947.
22. Mercadante S, Casuccio A, Fulfaro F, et al: Switching from morphine to methadone to improve analgesia and tolerability in cancer pain. J Clin Oncol 2001;19:2898-2904.
23. Parsons HA, de la Cruz M, El Osta B, et al: Methadone initiation and rotation in the outpatient setting for patients with cancer pain. Cancer 2010;116:520-528.
24. Jensen MP: The validity and reliability of pain measures in adults with cancer. J Pain 2003;4:2-21.
25. Bouhassira D, Attal N, Alchaar H, et al: Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire ( DN4). Pain 2005;114:29-36.
26. Farrar JT, Portenoy RK, Berlin JA, et al: Defining the clinically important difference in pain outcome measures. Pain 2000;88:287-294.
27. Farrar JT, Young JP, Jr., LaMoreaux L, et al: Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94: 149-158.
28. Joly F, Vardy J, Pintilie M, et al: Quality of life and/or symptom control in randomized clinical trials for patients with advanced cancer. Ann Oncol 2007;18:1935-1942.
29. Nicholson AB: Methadone for cancer pain. Cochrane Database Syst Rev 2007:CD003971.
30. Sotgiu ML, Valente M, Storchi R, et al: Cooperative N-methyl-D-aspartate (NMDA) receptor antagonism and mu-opioid receptor agonism mediate the methadone inhibition of the spinal neuron pain-related hyperactivity in a rat model of neuropathic pain. Pharmacol Res 2009;60:284-290.
31. Leppert W: The role of methadone in cancer pain treatment - a review. Int J Clin Pract 2009;63:1095-1109.
32. Bruera E, Palmer JL, Bosnjak S, et al: Methadone versus morphine as a first-line strong opioid for cancer pain: A randomized, double-blind study. J Clin Oncol 2004;22:185-192.
33. Moksnes K, Dale O, Rosland JH, et al: How to switch from morphine or oxycodone to methadone in cancer patients? A randomised clinical phase II trial. Eur J Cancer 2011; 47: 2463-2470.
34. Krantz MJ, Lewkowiez L, Hays H, et al: Torsade de pointes associated with very-high-dose methadone. Ann Intern Med 2002;137:501-504.
35. Pearson EC, Woosley RL: QT prolongation and torsades de pointes among methadone users: Reports to the FDA spontaneous reporting system. Pharmacoepidemiol Drug Saf 2005;14:747-753.
36. Krantz MJ, Kutinsky IB, Robertson AD, et al: Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes. Pharmacotherapy 2003; 23:802-805.
37. Walker PW, Klein D, Kasza L: High dose methadone and ventricular arrhythmias: A report of three cases. Pain 2003; 103:321-324.
38. Reddy S, Hui D, Palmer L, et al: The effect of oral methadone on the QTc interval in adnvanced cancer patient: A prospective pilot study. J Palliat Med 2010;13:33-38.
39. De Conno F, Groff L, Brunelli C, et al: Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients. J Clin Oncol 1996; 14:2836-2842.
40. Prommer E: Rotating methadone to other opioids: A lesson in the mechanisms of opioid tolerance and opioid-induced pain. J Palliat Med 2006;9:488-493.
41. Walker P, Palla S, Be-Lian P, et al: Switching from methadone to a different opioid: What is the analgesic dose ratio? J Palliat Med 2008;11:1103-1108.